![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Personal Screen | LSE:PSP | London | Ordinary Share | GB0003486585 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.085 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:8938P Personal Screening PLC 22 January 2007 For release 22 January 2007 Personal Screening Plc ("Personal Screening" or "the Company") (PSP.L) #25,000 Grant Awarded to Personal Screening Subsidiary to Develop Field Test for Arsenic in Drinking Water Personal Screening plc's ("Personal Screening") wholly owned subsidiary, Mermaid Diagnostics Limited ("Mermaid"), has won a grant of #25,000 to develop Mermaid's patented technology SafeTube, which is already commercially available as SmokeScreen, a test for nicotine metabolites in urine, as a test for arsenic contamination of potable water supplies. The grant was given from the Technology Transfer Fund (TTF), a #3.8m fund, managed by Birmingham Research and Development Ltd (BRDL), the University of Birmingham's technology transfer company. Significant investment in the World's poorest communities, where the supply of clean drinking water is a high priority, has provided new supplies, in the form of tube wells, to areas such as the Indian subcontinent. Unfortunately, many of these new wells are contaminated with the highly toxic substance, arsenic, as a result of local geology, whose chronic ingestion in small quantities may results in gangrene of the extremities and cancer, particularly of the skin, lung and bladder. Regular tests need to be carried out on these wells, usually located in rural areas, but laboratory testing is both time consuming and expensive. It is hoped that the SafeTube test will provide a rapid, sensitive and inexpensive alternative with immediate results, by alerting the population immediately whether the well has a dangerously high level of arsenic. In a recent report on the problem the World Health Organization (WHO) said there was an urgent need for "Simple, reliable, low-cost equipment for field measurement". Dr Dipander Chakraborti of the School of Environmental Sciences, Jadavpur University, Calcutta, believes as many as 330 million people across the subcontinent (India and Pakistan) could be at risk. Dr. Graham Cope, who developed the SafeTube technology, says: "Arsenic poisoning is a major problem on the Indian subcontinent and we believe the SafeTube technology can be successfully adapted to produce a robust, sensitive test which will protect the inhabitants of rural India and Bangladesh from chronic poisoning." Dr. Andy Mountain, Medical Technologies Manager, TTF, based at BRDL says: "We believe Mermaid Diagnostics has a good technology with a fine track record of applications and we fully support them in their efforts to develop a new test to help detect the contamination of water supplies, so important to the rural communities of the Indian Subcontinent." - ENDS - Editor's Notes *The latest WHO survey suggests around 70 million people are at risk of arsenic poisoning from drinking non potable water. *The effects of chronic ingestion of this substance range from skin pigmentation to gangrene of the extremities and cancer of the skin, lung and bladder. *Arsenic in drinking water is thought to pose the highest cancer risk ever found. Recent estimates from the WHO suggest that arsenic in drinking water will cause 200,000 to 270,000 deaths in Bangladesh alone. *45.5% of hand tube wells have arsenic contamination above the recommended levels. For further information, please contact: Personal Screening plc Michael Scorey, Chairman 01384 352 717 Mermaid Diagnostics Limited Dr Graham Cope 01384 352 717 Adventis Financial PR Chris Steele 020 7034 4759 This information is provided by RNS The company news service from the London Stock Exchange END MSCUUUKRBSRAURR
1 Year Personal Screening Chart |
1 Month Personal Screening Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions